Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling hope it could one day work in humans.

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins ...

Biotech Analyst Fadia, along with Dr. Justin Long, discuss the factors influencing adoption of Alzheimer’s disease treatments, including ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Richmond’s annual Alzheimer’s awareness walk came within a hair’s breadth of achieving its $925,000 goal on Saturday.

Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

This keeps many from being able to receive the top two Alzheimer's treatments, Leqembi and Kisunla. A majority, 58 percent, also said they would be more likely to vote for a candidate if they ...